Published in Ann N Y Acad Sci on January 01, 1990
Oxidative stress in β-thalassaemia and sickle cell disease. Redox Biol (2015) 0.84
Structural and functional studies indicating altered redox properties of hemoglobin E: implications for production of bioactive nitric oxide. J Biol Chem (2011) 0.83
Erythropoiesis in the absence of adult hemoglobin. Mol Cell Biol (2013) 0.78
Abnormal haemoglobins, Hb Takamatsu and Hb G-Szuhu, detected during the analysis of glycated haemoglobin (HbA1C) by high performance liquid chromatography. J Clin Pathol (2000) 0.78
Renal complications of beta-thalassemia major in children. Am J Blood Res (2014) 0.75
Unstable beta-globin mRNA in mRNA-deficient beta o thalassemia. Cell (1981) 3.80
A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med (1984) 3.07
Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol (1978) 2.07
The present status of the heterogeneity of fetal hemoglobin in beta-thalassemia: an attempt to unify some observations in thalassemia and related conditions. Ann N Y Acad Sci (1974) 1.99
Proliferation and maturation of human erythroid progenitors in liquid culture. Blood (1989) 1.78
The effects of protein conformation on the heme symmetry in high spin ferric heme proteins as studied by electron paramagnetic resonance. J Biol Chem (1971) 1.57
Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM (2008) 1.56
Brief report: tumor lysis syndrome following treatment with 2-chlorodeoxyadenosine for refractory chronic lymphocytic leukemia. N Engl J Med (1993) 1.51
Ovarian tissue banking in patients with Hodgkin's disease: is it safe? Fertil Steril (1998) 1.46
Demonstration of a natural antigalactosyl IgG antibody on thalassemic red blood cells. Blood (1983) 1.41
Activated oxygen and haemolysis. Br J Haematol (1975) 1.41
Studies on the stability of oxyhemoglobin A and its constituent chains and their derivatives. J Biol Chem (1971) 1.38
Cardiopulmonary assessment in beta-thalassemia major. Chest (1990) 1.26
Oxidative denaturation of red blood cells in thalassemia. Semin Hematol (1990) 1.24
Lipid membrane peroxidation in beta-thalassemia major. Blood (1976) 1.18
Denaturation of the normal and abnormal hemoglobin molecule. Semin Hematol (1974) 1.17
Role of haemichromes in the formation of inclusion bodies in haemoglobin H disease. Nature (1969) 1.12
Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease--a report of 4 cases. Ann Oncol (1995) 1.09
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood (1996) 1.08
beta 0-Thalassemia complicated by autoimmune hemolytic anemia. Globin synthesis during immunosuppressive therapy. Acta Haematol (1980) 1.06
The natural anti-alpha-galactosyl IgG on human normal senescent red blood cells. Br J Haematol (1986) 1.05
Essential cryofibrinogenemia. Clinical, pathological and immunological studies. Isr J Med Sci (1970) 1.05
Optic atrophy following treatment with cobalt chloride in a patient with pancytopenia and hypercellular marrow. Isr J Med Sci (1972) 1.05
Gonadotrophin, thyrotrophin and prolactin reserve in beta thalassaemia. Clin Endocrinol (Oxf) (1978) 1.04
In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol (1997) 1.02
A new polymorphism in the human beta-globin gene useful in antenatal diagnosis. J Clin Invest (1981) 1.02
Erythropoietin triggers a burst of GATA-1 in normal human erythroid cells differentiating in tissue culture. Nucleic Acids Res (1993) 1.00
Absence of beta mRNA in beta0-thalassemia in Kurdish Jews. Blood (1978) 1.00
Erythrocyte membrane skeleton abnormalities in severe beta-thalassemia. Blood (1987) 0.99
Novel treatment options in the severe beta-globin disorders. Br J Haematol (1995) 0.99
The demonstration of ferrihemochrome intermediates in heinz body formation following the reduction of oxyhemoglobin A by acetylphenylhydrazone. Biochim Biophys Acta (1975) 0.99
Superoxide dismutase in red blood cells: method of assay and enzyme content in normal subjects and in patients with beta-thalassemia (major and intermedia). J Lab Clin Med (1976) 0.98
Blood group phenotypes and hemoglobin S. An anthropologic study in two Israeli Arab communities. Acta Haematol (1976) 0.98
Mean corpuscular volume of heterozygotes for beta-thalassemia correlates with the severity of mutations. Blood (1992) 0.98
The two-step liquid culture: a novel procedure for studying maturation of human normal and pathological erythroid precursors. Stem Cells (1993) 0.97
Quantitative studies of ferritinlike iron in erythrocytes of thalassemia, sickle-cell anemia, and hemoglobin Hammersmith with Mössbauer spectroscopy. Proc Natl Acad Sci U S A (1979) 0.96
Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg (1982) 0.96
Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol (1993) 0.96
Blood group phenotypes and the origin of sickle cell hemoglobin in Sicilians. Acta Haematol (1978) 0.94
Visceral leishmaniasis: a difficult diagnosis and unusual causative agent. J Infect Dis (1991) 0.94
A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood. Br J Haematol (1999) 0.93
Two mutations in the beta-globin polyadenylylation signal reveal extended transcripts and new RNA polyadenylylation sites. Proc Natl Acad Sci U S A (1992) 0.92
Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation. Am J Hematol (1997) 0.91
Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. J Clin Invest (1989) 0.91
Nonspecific serum iron in thalassemia: quantitation and chemical reactivity. Am J Hematol (1979) 0.91
Expression of granulocytic functions by leukemic promyelocytic HL-60 cells: differential induction by dimethylsulfoxide and retinoic acid. Cell Differ (1987) 0.90
Homozygous beta0- and beta+ - thalassemia in Kurdish Jews and Arabs. Hemoglobin (1977) 0.90
In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood (1991) 0.90
Ultrastructural studies in -thalassaemia major. Br J Haematol (1973) 0.89
Formation of hemichromes from oxidized hemoglobin subunits. Ann N Y Acad Sci (1969) 0.89
The interaction of hemoglobin O Arab with Hb S and beta+ thalassemia among Israeli Arabs. Hum Genet (1985) 0.89
Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Br J Haematol (1979) 0.88
Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clin Endocrinol (Oxf) (1993) 0.88
Self-renewal and commitment to differentiation of human leukemic promyelocytic cells (HL-60). J Cell Physiol (1982) 0.88
Thromboembolic complications in beta thalassemia major. Acta Haematol (1992) 0.87
Relief of pruritus by cholestyramine in chronic liver disease. Isr J Med Sci (1965) 0.87
Phagocytosis of nucleated and mature beta thalassaemic red blood cells by mouse macrophages in vitro. Br J Haematol (1979) 0.87
Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem Pharmacol (1997) 0.87
Genetic and molecular diversity in nondeletion Hb H disease. Proc Natl Acad Sci U S A (1981) 0.86
Cross-linking of red blood cell membrane proteins induced by oxidative stress in beta thalassemia. FEBS Lett (1978) 0.86
Left ventricular function in beta-thalassemia and the effect of multiple transfusions. Am Heart J (1978) 0.86
Splenectomy in homozygous beta thalassaemia: a retrospective study of 30 patients. Br J Haematol (1975) 0.86
Adult and neonatal patterns of human globin gene expression are recapitulated in liquid cultures. Exp Hematol (1992) 0.86
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood (1995) 0.85
Vitamin E deficiency in beta-thalassemia major: changes in hematological and biochemical parameters after a therapeutic trial with alpha-tocopherol. Am J Clin Nutr (1979) 0.85
Growth of human normal erythroid progenitors in liquid culture: a comparison with colony growth in semisolid culture. Int J Cell Cloning (1991) 0.85
An electron microscopic study of the nuclear abnormalities in erythroblasts in beta-thalassaemia major. Br J Haematol (1974) 0.85
Isolation, characterization, and immunoprecipitation studies of immune complexes from membranes of beta-thalassemic erythrocytes. Blood (1992) 0.85
Protective effects of rutin against hemoglobin oxidation. Biochem Pharmacol (1994) 0.85
Sickle cell trait in a white Jewish family presenting as splenic infarction at high altitude. Am J Hematol (1988) 0.84
Dapsone-induced methemoglobinemia and hemolysis in the presence of familial hemoglobinopathy Hasharon and familial methemoglobin reductase deficiency. Isr J Med Sci (1981) 0.84
Oxidative damage to human red cells induced by copper and iron complexes in the presence of ascorbate. Biochim Biophys Acta (1989) 0.84
Haemichrome formation during the in vitro oxidation of Hb Köln. Nat New Biol (1973) 0.84
Tumour promoters induce macrophage differentiation in human myeloid cells from patients with acute and chronic myelogenous leukaemia. Br J Haematol (1981) 0.84
Disseminated visceral fusariosis treated with amphotericin B-phospholipid complex. Leuk Lymphoma (1993) 0.83
Recurrent transient bone marrow hypoplasia associated with pregnancy. Acta Haematol (1993) 0.83
Deferoxamine improves left ventricular function in beta-thalassemia. Arch Intern Med (1986) 0.83
Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes. Blood (1993) 0.83
Modulation of the maturation of human leukemic promyelocytes (HL-60) to granulocytes or macrophages. Leuk Res (1982) 0.83
Beta O-thalassemia intermedia. Blood (1978) 0.83
Haemoglobinopathies and red cell membrane function. Baillieres Clin Haematol (1993) 0.83
Erythropoietin activity in the serum of beta thalassemic patients. Scand J Haematol (1986) 0.83
Impaired neutrophil chemotaxis in patients with thalassaemia major. Br J Haematol (1993) 0.83
Studies in cryofibrinogenemia. Acta Haematol (1969) 0.82
Impaired erythrocyte calcium homeostasis in beta-thalassemia. Blood (1984) 0.82
High incidence of cholelithiasis in older patients with homozygous beta-thalassemia. Acta Haematol (1990) 0.82
A therapeutic trial in anemia of pregnancy. Isr J Med Sci (1968) 0.82
Successful full-term pregnancy in homozygous beta-thalassemia major: case report and review of the literature. Obstet Gynecol (1989) 0.82
Abnormal low and high density lipoproteins in homozygous beta-thalassaemia. Br J Haematol (1991) 0.82
The effect of an antiserotonin agent pizotifen on platelet aggregability in migraine patients. J Neurol Neurosurg Psychiatry (1980) 0.82
Molecular analysis of beta-thalassemia in Vietnam. Hemoglobin (2000) 0.82
Effect of extracellular hemin on hemoglobin and ferritin content of erythroleukemia cells. J Cell Physiol (1987) 0.81
Ultrastructure of the inclusion bodies and nuclear abnormalities in beta-thalassemic erythroblasts. Ann N Y Acad Sci (1974) 0.81
Alterations in the red blood cell membrane and the effect of vitamin E on osmotic fragility in beta-thalassemia major. Isr J Med Sci (1976) 0.81
A naturally occurring anti-alpha-galactosyl IgG recognizing senescent human red cells. Prog Clin Biol Res (1985) 0.81
Pulmonary thromboembolism in thalassemia intermedia patients. Haematologica (1999) 0.81
Calcium transport and ultrastructure of red cells in beta-thalassemia intermedia. Blood (1988) 0.80
Platelet survival in patients with beta-thalassemia. Am J Hematol (1989) 0.80
Hemoglobinopathies in Israel. Hemoglobin (1983) 0.80
Inadequate utilization of routine electronic RBC counts to identify beta thalassemia carriers. Am J Public Health (1988) 0.80